about
The identification of a selective dopamine D2 partial agonist, D3 antagonist displaying high levels of brain exposureA combinatorial approach to [1,5]benzothiazepine derivates as potential antibacterial agents.Solid-phase synthesis of combinatorial libraries based on enatiomerically pure (1S,2S,4R,5S)-4,5-dihydroxycyclohexan-1,2-dicarboxylic acid scaffolds.Lesopitron (Esteve).UK-315716/UK-240455. Pfizer.Targeting cystalysin, a virulence factor of treponema denticola-supported periodontitis.Occupancy of brain dopamine D3 receptors and drug craving: a translational approach.Recent advances in the development of dopamine D3 receptor antagonists: a medicinal chemistry perspective.Dopamine D3 receptor antagonists: a patent review (2007 - 2012).Triple monoamine uptake inhibitors.Novel, Selective, and Developable Dopamine D3 Antagonists with a Modified "Amino" Region.1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.Oxa-azaspiro derivatives: a novel class of triple re-uptake inhibitors.Novel morpholine scaffolds as selective dopamine (DA) D3 receptor antagonists.Synthesis and pharmacological characterization of 5-phenyl-2-[2-(1-piperidinylcarbonyl)phenyl]-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-1-ones: a new class of Neuropeptide S antagonists.Exploration of the amine terminus in a novel series of 1,2,4-triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists.[3-azabicyclo[3.1.0]hex-1-yl]phenyl-benzenesulfonamides as selective dopamine D3 antagonists.Pyrrolo[1,2-a]pyrazine and pyrazolo[1,5-a]pyrazine: novel, potent, and selective series of Vasopressin 1b receptor antagonists.A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane tempTriazolyl azabicyclo[3.1.0]hexanes: A class of potent and selective dopamine D(3) receptor antagonists.1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists.A new alternative synthesis of 5-cyanophthalide, a versatile intermediate in the preparation of the antidepressant drug citalopram.Synthesis and pharmacological characterisation of a conformationally restrained series of indole-2-carboxylates as in vivo potent glycine antagonists.Synthesis and pharmacological characterisation of 2,4-dicarboxy-pyrroles as selective non-competitive mGluR1 antagonists.2,4-Dicarboxy-pyrroles as selective non-competitive mGluR1 antagonists: further characterization of 3,5-dimethyl pyrrole-2,4-dicarboxylic acid 2-propyl ester 4-(1,2,2-trimethyl-propyl) ester and structure-activity relationships.Benzoazepine derivative as potent antagonists of the glycine binding site associated to the NMDA receptor.2,4-Dicarboxy-pyrroles as selective non-competitive mGluR1 antagonists: an exploration of the role of the pyrrolic scaffold.Enantiomerically pure tetrahydroquinoline derivatives as in vivo potent antagonists of the glycine binding site associated to the NMDA receptor.Stereoselective synthesis and preliminary evaluation of (+)- and (-)-3-methyl-5-carboxy-thien-2-yl-glycine (3-MATIDA): identification of (+)-3-MATIDA as a novel mGluR1 competitive antagonist.3-Methyl pyrrole-2,4-dicarboxylic acid 2-propyl ester 4-(1,2,2-trimethyl-propyl) ester: an exploration of the C-2 position. Part II, A solid-phase approach.3-Methyl pyrrole-2,4-dicarboxylic acid 2-propyl ester 4-(1,2,2-trimethyl-propyl) ester: an exploration of the C-2 position. Part I.1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.Dopamine D3 receptor antagonists: the quest for a potentially selective PET ligand. Part 3: Radiosynthesis and in vivo studies.Dopamine D3 receptor antagonists: the quest for a potentially selective PET ligand. Part one: lead identification.Dopamine D(3) receptor antagonists: The quest for a potentially selective PET ligand. Part two: Lead optimization.1,2,4-triazol-3-yl-thiopropyl-tetrahydrobenzazepines: a series of potent and selective dopamine D(3) receptor antagonists.Substituted tetraazaacenaphthylenes as potent CRF1 receptor antagonists for the treatment of depression and anxiety.Phenylethynyl-pyrrolo[1,2-a]pyrazine: a new potent and selective tool in the mGluR5 antagonists arena.New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.
P50
Q28273139-4305725F-C9D9-4452-8886-1ABD8BCCC163Q30986136-693CB266-D462-4AE5-AFE5-F752155EF750Q31117947-2C90231D-73FC-4AE3-B240-9831CAE73256Q34435341-330522D8-144B-4748-9548-B44564FDCD4DQ34562735-871796F5-B17C-4425-A7F8-ED4C33589312Q35116929-A534A189-8F06-49BA-8D01-6032A74D0E28Q36480118-BE25B6AB-5535-4123-9DBC-233A36C9709DQ37855718-76EAB3E7-6CE3-49C4-B3EE-45B6DE67FA0FQ38071135-089F0185-8992-4BD9-8AAA-293E0022438EQ38162938-83DDF7AA-5509-4A18-83B1-84E991CF4EC6Q39252003-D7B9FA94-937A-45B0-83EC-83A97A34625CQ39737426-90B7412F-D47E-4729-89BD-242684D4C164Q39746374-A21EA3A2-F350-4E6F-B323-482543B7B5AAQ40086850-62277AE6-D334-4988-8A55-13DE0EC03F2DQ42833771-D5B0B7FF-0C58-444F-AA66-260EF421900CQ42907954-3B74BAC5-7FCE-4EA9-86CB-D0EF335AD233Q42943471-A541C9AF-D8D6-48D6-82CB-09C838915563Q42950786-48BDA16D-452B-4991-A53B-55B113773881Q43007478-9D524CCD-C8A4-47AB-BD63-15C85F53F210Q43128275-43CF8FCF-C89F-4B1A-9C89-6D83D5447A53Q43248104-EBD9126D-FC6D-463E-8718-22AD65FDA11AQ43779754-A4E38B39-02F2-4401-B372-FE856E2C7F76Q43805727-59011F2F-AD14-4C46-A4B7-9869298AF994Q44241682-1306CA45-9D22-4548-94C7-BE6CEA952B64Q44472657-9512BA3C-ED33-453A-8C40-9FC70A4F1670Q44588324-F3FE5C9A-23B6-4C1C-AE01-BA1D394B121CQ44593782-15B9DDA0-DDD7-4108-ADA8-036C44A5500DQ44614212-1DDABB10-F9B4-4DC3-A3C3-2D6195E77FAAQ44761655-5B54475F-0C59-4CD3-8E1F-82D8AAC9A722Q44761664-F591CD3F-8DD3-4D85-A126-32A6C30DDFC9Q44779033-D2ECC773-A2CC-4B24-9966-459A765A2767Q45041069-E1FB9FFF-55F7-434E-9046-237B14EA7C22Q45918561-9A2AB5E7-984F-4CEF-8DA1-2D10ED0E7EF4Q45949489-B72E2E8E-D17C-4557-8ABE-1FDAB9CF2AB7Q45954407-67DF3485-D701-49A6-B7F8-57A6AEB460D0Q46278485-13706A1D-F995-4B34-A931-C14F52B4EE36Q46537363-535847D7-39E5-4664-9A84-6FDB82A6680BQ46730051-00A71543-61E3-4A6C-8BD2-8255734E540EQ46772537-AAAF626A-0F38-43B6-9E89-53FA96867036Q46820906-A89F0EB8-5F13-4411-83F5-4C3E9699C792
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Fabrizio Micheli
@ast
Fabrizio Micheli
@en
Fabrizio Micheli
@es
Fabrizio Micheli
@nl
Fabrizio Micheli
@sl
type
label
Fabrizio Micheli
@ast
Fabrizio Micheli
@en
Fabrizio Micheli
@es
Fabrizio Micheli
@nl
Fabrizio Micheli
@sl
prefLabel
Fabrizio Micheli
@ast
Fabrizio Micheli
@en
Fabrizio Micheli
@es
Fabrizio Micheli
@nl
Fabrizio Micheli
@sl
P106
P1153
36960068000
P21
P31
P496
0000-0002-1871-5288